NASDAQ : RCKT
Rocket Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.54 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 278.83M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 271.14M |
| Enterprise Value | 12.19M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 109.77M |
| Shares Outstanding | 109.77M |
| Shares Change (YoY) | +8.61% |
| Shares Change (QoQ) | +2.12% |
| Owned by Insiders (%) | 3.97% |
| Owned by Institutions (%) | 76.36% |
| Float | 87.62M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 35.04 |
| PB Ratio | 0.72 |
| P/TBV Ratio | 0.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.24 |
| Quick Ratio | 9.06 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -101.42 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -4.77% |
| Return on Assets (ROA) | -28.42% |
| Return on Invested Capital (ROIC) | -31.03% |
| Return on Capital Employed (ROCE) | -48.98% |
| Weighted Average Cost of Capital (WACC) | 6.90% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$85,396 |
| Employee Count | 202 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 8.62M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -34.48% |
| 50-Day Moving Average | 2.94 |
| 200-Day Moving Average | 3.45 |
| Relative Strength Index (RSI) | 46.53 |
| Average Volume (20 Days) | 2,159,085 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 16.28M |
| Short Previous Month | 15.05M |
| Short % of Shares Out | 14.83% |
| Short % of Float | 18.58% |
| Short Ratio (days to cover) | 6.83 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -191.88M |
| Pretax Income | -8.63M |
| Net Income | -17.25M |
| EBITDA | -182.18M |
| EBIT | -191.88M |
| Earnings Per Share (EPS) | -$0.15 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 283.75M |
| Total Debt | 24.80M |
| Net Cash | 258.95M |
| Net Cash Per Share | $2.36 |
| Equity (Book Value) | 368.83M |
| Book Value Per Share | 3.37 |
| Working Capital | 258.23M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -170.27M |
| Capital Expenditures | -127,000 |
| Depreciation & Amortization | 9.71M |
| Net Borrowing | -3,000 |
| Free Cash Flow | -170.39M |
| FCF Per Share | -$1.55 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.61% |
| Shareholder Yield | -8.61% |
| Earnings Yield | -6.23% |
| FCF Yield | -63.10% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $8.58 |
| Price Target Difference | 247.33% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |